SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) reported Q1 EPS of ($0.47), $0.18 worse than the analyst estimate of ($0.29).

For earnings history and earnings-related data on SELLAS Life Sciences Group, Inc. (SLS) click here.